Innovative commercial strategy, delivering results.
Cytomedix, Inc. (OTCQX:CMXI) is an autologous regenerative therapies company. Our synergistic blood and bone marrow fractionation techniques are intended to provide patients and clinicians with innovative treatment options by harnessing the regenerative capacity of a patient’s own cells. Commercially, we market advanced platelet rich plasma systems in the US and Internationally. Our regenerative cell therapies pipeline using proprietary ALDH bright cell ("ALDHbr") technology, is based on a marker of biologic activity to identify pluri-potential progenitor cells. Currently, a Phase 2 trial for the treatment of ischemic stroke using ALDHbr Bright Cells is underway.
The Company’s commercial development results set us apart from other regenerative medicine players. Key milestones include:
- AutoloGel PRP FDA clearance for chronic wounds (2007)
- Angel PRP System acquisition (2010)
- Aldagen “adult stem cell technology” acquisition (2012)
- CMS coverage for PRP chronic wounds (2012)
- CMS coding for PRP in chronic wounds (2013)
The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound, hair transplantation and orthopedics markets. We seek to monetize other product candidates in our pipeline through strategic partnerships, out-licensing, or direct sales. Each of our systems and product candidates addresses multi-billion dollar markets and possesses distinct competitive advantages over existing therapies. The technological platforms underpinning our products leverage the human body’s naturally-occurring proteins and other biological actors.
Our technologies are protected by a growing list of families of granted and pending patents in the U.S. and internationally as well as proprietary methodologies and know-how.
Headquartered in Gaithersburg, MD, with research and development based in Durham, NC, we employ 45 people, with scientific, clinical, sales, marketing, regulatory, operations and financial expertise. We have distribution partners in Europe, Japan, Middle East, Canada, Australia and New Zealand.